NCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT06959433 2026-02-27
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Ankara University
Phase 3 Not yet recruiting
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT07200830 2025-10-01
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology
Phase 3 Not yet recruiting
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT03511664 2025-01-13
VISION
Endocyte
Phase 3 Completed
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting